Insys Therapeutics Inc. (NASDAQ:INSY)’s share price traded down 1.1% on Monday . The stock traded as low as $14.70 and last traded at $14.82, with a volume of 228,247 shares. The stock had previously closed at $14.98.

A number of equities research analysts have commented on the stock. Zacks Investment Research upgraded shares of Insys Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, June 13th. Oppenheimer Holdings Inc. restated a “hold” rating on shares of Insys Therapeutics in a research note on Saturday, April 30th. Piper Jaffray Cos. restated an “overweight” rating and set a $46.00 target price on shares of Insys Therapeutics in a research note on Thursday, March 24th. Jefferies Group decreased their target price on shares of Insys Therapeutics from $23.00 to $17.00 and set a “buy” rating on the stock in a research note on Tuesday, April 12th. Finally, Royal Bank Of Canada restated an “outperform” rating and set a $32.00 target price (down previously from $44.00) on shares of Insys Therapeutics in a research note on Tuesday, April 12th. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Insys Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $23.83.

The company has a market cap of $1.06 billion and a PE ratio of 21.47. The stock’s 50 day moving average is $14.38 and its 200-day moving average is $16.58.

Insys Therapeutics (NASDAQ:INSY) last issued its quarterly earnings results on Thursday, April 28th. The specialty pharmaceutical company reported $0.11 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.07 by $0.04. During the same quarter in the previous year, the firm posted $0.63 EPS. The business had revenue of $62 million for the quarter, compared to analysts’ expectations of $61.31 million. Insys Therapeutics’s revenue was down 12.4% on a year-over-year basis. On average, equities analysts expect that Insys Therapeutics Inc. will post $0.36 EPS for the current year.

In other news, major shareholder John N. Kapoor Trust Dated Sept bought 50,000 shares of the company’s stock in a transaction that occurred on Thursday, May 12th. The shares were purchased at an average price of $12.84 per share, for a total transaction of $642,000.00. Following the completion of the transaction, the insider now directly owns 31,982 shares in the company, valued at $410,648.88. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Theodore H. Stanley sold 16,000 shares of the company’s stock in a transaction that occurred on Monday, June 6th. The shares were sold at an average price of $16.27, for a total value of $260,320.00. Following the completion of the sale, the director now owns 18,000 shares in the company, valued at approximately $292,860. The disclosure for this sale can be found here.

Other large investors have recently modified their holdings of the company. Globeflex Capital L P raised its stake in shares of Insys Therapeutics by 99,000.0% in the fourth quarter. Globeflex Capital L P now owns 39,640 shares of the specialty pharmaceutical company’s stock worth $1,135,000 after buying an additional 39,600 shares in the last quarter. California State Teachers Retirement System raised its stake in Insys Therapeutics by 1.8% in the fourth quarter. California State Teachers Retirement System now owns 43,625 shares of the specialty pharmaceutical company’s stock valued at $1,249,000 after buying an additional 754 shares in the last quarter. ProShare Advisors LLC raised its stake in Insys Therapeutics by 7.5% in the fourth quarter. ProShare Advisors LLC now owns 61,353 shares of the specialty pharmaceutical company’s stock valued at $1,757,000 after buying an additional 4,305 shares in the last quarter. Bank of Montreal Can raised its stake in Insys Therapeutics by 9.4% in the fourth quarter. Bank of Montreal Can now owns 66,646 shares of the specialty pharmaceutical company’s stock valued at $1,909,000 after buying an additional 5,733 shares in the last quarter. Finally, Sei Investments Co. raised its stake in Insys Therapeutics by 6.6% in the fourth quarter. Sei Investments Co. now owns 78,945 shares of the specialty pharmaceutical company’s stock valued at $2,260,000 after buying an additional 4,854 shares in the last quarter.

Insys Therapeutics, Inc is a commercial-stage specialty pharmaceutical company. The Company develops and commercializes supportive care products. The Company’s product Subsys, is a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and a single-use product that delivers fentanyl, an opioid analgesic, for transmucosal absorption underneath the tongue.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.